Up-to-date List of Lupron Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Lupron Medical Research Studies

RankStatusStudy
1 Recruiting GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases
Conditions: Lupus Erythematosus, Systemic;   Systemic Vasculitis;   Isolated Angiitis of Central Nervous System;   Lung Disease With Systemic Sclerosis;   Lung Disease Interstitial Diffuse
Interventions: Drug: depot leuprolide acetate 3.75 mg;   Drug: Placebo
Outcome Measures: anti-mullerian hormone (AMH) measured as a continuous variable, specifically assessing the intra-person change from study entry (Day 0) to 6-month post-intervention visit;   Proportion of patients with AMH of ≤1.0 ng/mL vs >1 ng/mL, presence of menses, presence of either an AMH level of >1 ng/mL OR antral follicle count of >4. Continuous measures include: antral follicle count (AFC), ovarian volume, and FSH.
2 Recruiting Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation
Conditions: Acute Lymphocytic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome RAEB 1
Interventions: Drug: Lupron;   Drug: 18F FLT;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Tacrolimus;   Drug: Total Body Irradiation
Outcome Measures: To determine if Lupron improves B lymphocyte reconstitution after HSCT.;   To assess whether 18F FLT PET/CT could predict early engraftment/immune reconstitution in marrow and thymus after allogeneic HSCT.;   To investigate whether Lupron will decrease the incidence of acute or chronic GVHD without altering GVT after allogeneic HSCT.;   To evaluate if Lupron decreases the incidence of infections after HSCT.
3 Recruiting Palifermin With or Without Leuprolide Acetate Versus Control for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
Conditions: Leukemia;   Multiple Myeloma;   Myelodysplastic Syndrome;   Non-Hodgkin's Lymphoma
Interventions: Biological: Palifermin;   Biological: Lupron;   Other: without the addition of palifermin or Lupron;   Procedure: peripheral blood stem cell transplantation
Outcome Measures: a CD4+ T cell count of greater than 200;   Overall Survival;   Transplant Related Mortality;   Incidence of infections;   Relapse
4 Recruiting Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)
Conditions: Fibrolamellar Carcinoma;   Fibrolamellar Liver Cancer
Interventions: Drug: everolimus;   Drug: letrozole plus leuprolide;   Drug: combination of everolimus, letrozole and leuprolide
Outcome Measures: efficacy endpoints for Part 1 of the study is progression-free survival at 6 months (PFS6);   median PFS;   median overall survival (OS);   response rate;   to evaluate toxicity in patients;   correlative serum;   tissue biomarker studies;   to evaluate safety in patients
5 Not yet recruiting A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease
Condition: Metastatic Prostate Cancer
Intervention: Drug: Eligard
Outcome Measures: Changes from baseline of Testosterone levels in serum;   Changes from baseline of PSA level in serum;   Changes from baseline of PCA3 score in urine;   Changes from baseline of Number of PSA mRNA copies in blood/PBMC;   Changes from baseline of Number of PCA3 mRNA copies in blood/PBMC;   Changes from baseline of Number of TMPRSS2-ERG mRNA copies in blood/PBMC;   Number of Adverse Events from screening to the end of study visit (as reported by the investigator based on Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.3)
6 Recruiting Phase III Study : Enantone LP 11.25 mg (Leuprorelin) Effect on the Histological Progression of Indolent Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Enantone LP 11.25 mg (1 injection) + Surveillance;   Other: active surveillance
Outcome Measures: Comparison of the number of patients with negative biopsies at 12 months;   Gleason score Anxiety evaluation (HADS)/ Erectile function evaluation;   the progression over time of disease clinical symptoms (IPSS score);   the tumour radiological progression by dynamic MRI;   the PSA levels progression;   the anxiety score on HAD Scale;   the International Index of Erectile Function (IIEF-5) Questionnaire
7 Recruiting Preservation of Ovarian Function After Hematopoietic Cell Transplant
Conditions: Multiple Myeloma;   Non-Hodgkin Lymphoma;   Hodgkin Disease;   Acute Myeloid Leukemia;   Myeloproliferative Disorders
Interventions: Drug: Leuprolide;   Biological: hematopoietic cell transplant;   Biological: reduced intensity allogeneic HCT
Outcome Measures: Comparison of Number of Patients with Ovarian Failure;   Comparison of Number of Participants Who Stopped Menstrual Bleeding;   Comparison of Follicle Stimulating Hormone (FSH) Levels;   Comparison of Number of Participants Who Resumed Menstrual Cycles;   Comparison of Leuprolide Hormone (LH) Levels;   Comparison of Antimullerian Hormone (AMH) Levels After Transplant
8 Unknown  Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess
Conditions: Hyperandrogenemia;   Obesity;   Polycystic Ovary Syndrome
Interventions: Drug: Leuprolide;   Drug: Dexamethasone;   Drug: recombinant human chorionic gonadotropin
Outcome Measures: 17 hydroxyprogesterone responses to rhCG before and 4 weeks after depot leuprolide administration;   Ovarian hormone precursor responses to rhCG before and 4 weeks after depot leuprolide administration
9 Recruiting An Observational Study Looking at How Well the Drug Eligard Works and How Well it is Tolerated by the Body of Patients With Advanced Prostate Carcinoma in the Russian Federation
Condition: Advanced Prostate Carcinoma
Intervention: Drug: Eligard 45 mg Exposure
Outcome Measures: Percentage change in total serum PSA;   Percentage change in testosterone levels;   Number of adverse drug reactions;   Mean change in QoL based on EuroQOL five dimensions questionnaire (EQ-5D)
10 Recruiting A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy
Condition: Prostate Cancer
Interventions: Drug: TAP-144-SR(6M);   Drug: TAP-144-SR(3M)
Outcome Measure: The rate of suppression of serum testosterone to castrate level
11 Recruiting A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer
Condition: Premenopausal Breast Cancer
Interventions: Drug: TAP-144-SR(6M);   Drug: TAP-144-SR(3M)
Outcome Measure: The suppression rate of serum estradiol(E2) to menopausal level
12 Recruiting Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone
Condition: Prostate Cancer
Interventions: Drug: Lupron;   Drug: Zoladex;   Drug: Degarelix;   Drug: Abiraterone Acetate;   Drug: Prednisone
Outcome Measure: Prostate Specific Antigen (PSA) Free Survival
13 Unknown  Leuprolide in Treating Adults With Hypogonadotropism
Condition: Hypogonadism
Intervention: Drug: leuprolide
Outcome Measure:
14 Unknown  Leuprolide in Determining the Cause of Gonadotropin Deficiency
Condition: Hypogonadism
Interventions: Drug: gonadotropin releasing hormone;   Drug: leuprolide
Outcome Measure:
15 Recruiting Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic T2-T3N0 Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Docetaxel;   Radiation: Radiation Therapy;   Drug: Casodex and Zoladex (or Lupron)
Outcome Measure: To determine whether greater than or equal to 95% of patients who undergo adjuvant hormonal therapy, radiation therapy and docetaxel after a radical prostatectomy can safely tolerate and complete this regimen.
16 Recruiting Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: docetaxel;   Drug: goserelin acetate;   Drug: leuprolide acetate;   Procedure: conventional surgery
Outcome Measures: 3-year biochemical progression-free survival (bPFS) rate;   5-year bPFS rate and bPFS;   Time to clinical local recurrence;   Time to metastatic disease progression;   Unacceptable toxicity;   Prostate cancer-specific-free survival;   Disease progression;   Overall survival;   Death
17 Not yet recruiting The Effect of GnRH Agonist Administered in the Luteal Phase on ART Cycle Outcomes
Condition: Infertility
Interventions: Drug: Leuprolide acetate;   Drug: vaginal progesterone;   Drug: 4 mg oral estradiol valerate
Outcome Measures: Live Birth Rate;   Ongoing pregnancy;   miscarriage;   OHSS
18 Recruiting Natural Cycle In Vitro Fertilization
Condition: Natural Cycle in Vitro Fertilization (IVF)
Interventions: Procedure: Uterine Aspiration and Endometrial Biopsy/Embryo Biopsy;   Drug: Leuprolide Acetate;   Drug: Human Chorionic Gonadotropin (hCG)
Outcome Measures: Endometrial Changes;   Aneuploidy Rates
19 Not yet recruiting A Phase II Study of Androgen Deprivation Therapy With or Without PD 0332991 in RB-Positive Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: PD 0332991;   Drug: Bicalutamide;   Drug: Zoladex;   Drug: Lupron Depot
Outcome Measures: Number of patients who achieve a PSA < 4ng/mL after seven months of protocol treatment in each arm;   Frequency of adverse events;   Duration of therapy;   Proportion of patients who achieve undetectable PSA (<0.2ng/mL);   Time to biochemical progression;   Time to clinical progression;   Frequency of dose modification;   Frequency of treatment delay
20 Recruiting Metabolic Study of Women With Polycystic Ovary Syndrome and Sleep Apnea
Conditions: Polycystic Ovary Syndrome;   Obstructive Sleep Apnea
Interventions: Drug: Depot Lupron followed by estrogen plus placebo;   Drug: Depot Lupron followed by progesterone plus placebo.;   Device: CPAP
Outcome Measures: Sex steroid levels;   Sleep recording/polysomnography;   Frequently sampled IVGTT;   24-hour hormonal profiles

These studies may lead to new treatments and are adding insight into Lupron etiology and treatment.

A major focus of Lupron research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Lupron

© Copyright 2019.

If you think you may have a medical emergency, call your doctor or 911 immediately.

By accessing this website, you are indicating your acknowledgement and acceptance of these Terms of Use. These Terms of Use are subject to change by WinFirst LLC at any time in its discretion. Your use of WinFirst LLC Site after such changes are implemented constitutes your acknowledgement and acceptance of the changes. Please consult these Terms of Use regularly. PatientsVille.com does not provide medical advice, diagnosis or treatment. The information contained on PatientsVille.com site has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of adverse drug reactions or for establishing or changing of patient treatments.

Privacy | Terms | Contact us
Share
Popular Pages